Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan

Guidance on using tocilizumab for juvenile idiopathic arthritis

(2011) Shumpei Yokota et al.   Modern Rheumatology

Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis

(2011) Tomoyuki Imagawa et al.   Modern Rheumatology

Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials

(2011) Masaaki Mori et al.   Modern Rheumatology

2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features

(2011) Timothy Beukelman et al.   ARTHRITIS CARE & RESEARCH

Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases

(2009) G R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations

(2009) S. Ringold et al.   RHEUMATOLOGY

Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study

(2008) Nobuyuki Miyasaka et al.   Modern Rheumatology

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

(2008) Daniel J. Lovell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Health related quality of life survey about children and adolescents with juvenile idiopathic arthritis

(2008) Bouchra Amine et al.   RHEUMATOLOGY INTERNATIONAL